FDA Authorizes ZYN Nicotine Pouches to Carry Modified Risk Claim as Safer Alternative to Cigarettes

The U.S. Food and Drug Administration has authorized 20 ZYN (搜索)搜索该药品 nicotine pouch products to carry a specific "modified risk" claim, marking the first time regulators have formally endorsed the message that switching completely from cigarettes to nicotine pouches reduces health risks. Going forward, these products—manufactured by Swedish Match查看公司主页, a subsidiary of Philip Morris International (搜索)搜索该公司—will be permitted to state: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer (搜索)搜索该疾病, heart disease (搜索)搜索该疾病, lung cancer (搜索)搜索该疾病, stroke (搜索)搜索该疾病, emphysema (搜索)搜索该疾病, and chronic bronchitis (搜索)搜索该疾病."

The decision, issued on June 30, represents a significant regulatory milestone in the rapidly expanding nicotine pouch category. The FDA's Modified Risk Tobacco Product (MRTP) order applies to 10 ZYN (搜索)搜索该药品 flavors at each of two strengths—3 milligrams and 6 milligrams—and is valid for five years unless renewed or withdrawn.

The Science Behind the Decision

The FDA's authorization aligns with a growing body of scientific evidence demonstrating that nicotine pouches carry substantially lower health risks than combustible cigarettes. A 2023 randomized controlled study found that individuals who switched from cigarettes to nicotine pouches experienced significantly lower exposure to harmful chemicals within just one week. Those who switched saw their exposure rate reduced by approximately 42 percent to 96 percent compared to the group that continued smoking—a reduction level similar to that observed in participants who quit nicotine products entirely.

The researchers concluded that "the substantial reduction in harmful and potentially harmful constituent exposure" suggests that switching from cigarettes to nicotine pouches "may present a harm reduction opportunity for adults who smoke."

Additional studies support the potential of nicotine pouches as a harm-reduction tool. A 2025 cross-sectional study of medical students in Saudi Arabia found that 62.9 percent of nicotine pouch users reported quitting smoking entirely, and "more than half noted health improvements." A 2024 randomized controlled trial published in Nicotine & Tobacco Research demonstrated that low-income adults who smoked daily and were not planning to quit significantly reduced their cigarette consumption after being given nicotine pouches—from 15 cigarettes per day to approximately eight after two months.

"There is no question that the FDA's approval of [PMI] reduced risk claim is a huge advance for smokers, because Zyn (搜索)搜索该药品 delivers nicotine in a satisfying and enjoyable manner for a microscopic fraction of the health risks of smoking," said Brad Rodu, a professor of medicine at the University of Louisville and co-author of the first study of adult interest in ZYN, published in 2020. That study found the most popular reason for using ZYN pouches was that they are "less harmful to my health than other tobacco products," followed by "ease of use."

Raymond Niaura, a psychologist and tobacco dependence expert at New York University, added: "I hope that current cigarette smokers will take heed of this information, and that it will encourage switching from cigarette smoking to use of nicotine pouch products."

Regulatory Guardrails and Caveats

The FDA's authorization comes with important limitations. The ruling applies only to the 20 specific ZYN (搜索)搜索该药品 products, not all nicotine pouches. Furthermore, the reduced-risk finding applies exclusively to adults who completely switch from cigarettes—those who continue to use cigarettes or vapes alongside pouches will not obtain the same benefit.

"FDA's review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices," said Bret Koplow, acting director of the FDA's Center for Tobacco Products. He emphasized that the decision "informs adults who smoke about the lower risks associated with these products."

The agency also stressed that there is no safe tobacco product and that fully quitting all tobacco and nicotine products remains the best option for health. Swedish Match查看公司主页 is required to monitor real-world usage and report back to the FDA.

A Rapidly Growing Market

The regulatory green light arrives as the nicotine pouch category experiences explosive global growth. According to a recent World Health Organization report, global retail sales of nicotine pouches reached 23.4 billion units in 2024, an increase of more than 50 percent from the previous year. The WHO has also warned that nicotine pouches are spreading so rapidly that regulation is struggling to keep pace in many countries, and that brands are increasingly using social media, influencers, and youth-oriented marketing to promote them.

Public health officials remain cautious. The WHO has flagged concerns that nicotine pouches are becoming increasingly popular among adolescents and young adults because of their "strong youth appeal and high addiction potential," raising questions about whether products initially marketed to smokers could also attract new users.

Consumer Awareness Gap

Despite the growing evidence base, many Americans remain confused about the relative risks of nicotine products. In one survey of young adults from Southern California, nearly half said they were unsure whether nicotine pouches were more or less harmful than cigarettes, while only about 1 in 5 correctly identified them as less harmful. The FDA's decision now enables smokers to be informed of the reduced risk directly on ZYN (搜索)搜索该药品 packaging, potentially addressing this knowledge gap.